The cost of trials used to support the initial FDA approval of risdiplam (Evrysdi)
risdiplam
Timeline: Development of Risdiplam
Proposal for Addition Of Risdiplam to WHO Model List Of Essential Medicines, for the treatment of Spinal Muscular Atrophy (SMA).
On November 1, 2024, Knowledge Ecology International (KEI) submitted a proposal for the addition of risdiplam to the World Health Organization’s (WHO) Model List of Essential Medicine (EML). You can access the full proposal here: risdiplam2WHOEML1Nov2024 The EML, updated every… Continue Reading
KEI asks WHO to include risdiplam, treatment for Spinal Muscular Atrophy, on the Essential Medicines List (EML)
KEI letter to Roche requesting voluntary license to patents on risdiplam, a treatment for Spinal Muscular Atrophy (SMA)
This is a letter to Roche requesting a voluntary license to the patents on risdiplam, a treatment for Spinal Muscular Atrophy (SMA). KEI-Risdiplan-patent-license-request-8july2022 This was the August 5, 2022 response from Roche. Roche-Response-to-Risdiplam-license-request–5Aug2022 KEI wrote to Roche again on February… Continue Reading
risdiplam
Risdiplam, originally developed under contract with the SMA Foundation by PTC Therapeutics and licensed to Roche for sale under the brand name Evrysdi, is a medication used to treat spinal muscular atrophy and the first oral medication approved to treat… Continue Reading